Tea consumption and its effects on primary and secondary prevention of coronary artery disease: Qualitative synthesis of evidence from randomized controlled trials.

C-reactive protein Coronary artery disease Endothelial function Epigallocatechin gallate Low density lipoprotein Tea consumption

Journal

Clinical nutrition ESPEN
ISSN: 2405-4577
Titre abrégé: Clin Nutr ESPEN
Pays: England
ID NLM: 101654592

Informations de publication

Date de publication:
02 2021
Historique:
received: 08 09 2020
revised: 27 10 2020
accepted: 10 11 2020
entrez: 25 1 2021
pubmed: 26 1 2021
medline: 25 9 2021
Statut: ppublish

Résumé

There is a general interest in understanding how the consumption of tea impacts cardiovascular function in individuals at risk of developing cardiovascular disease (CVD). The current review focuses on evidence from randomized controlled trials (RCTs) reporting on associations between tea consumption and endothelial function, in the primary and secondary prevention of coronary artery disease (CAD). PubMed, EMBASE, and Google Scholar databases/search engines were used to identify eligible studies. Included studies had to report on the impact of tea supplementation of endothelial function or CAD related markers. In addition to flow-mediated dilation (FMD), makers of oxidative stress and inflammation such as oxidized low-density lipoprotein and C-reactive protein were considered as determinants of endothelial function. A total of 34 RCTs met the inclusion criteria, and these reported on the impact of tea consumption on endothelial function in individuals at risk of CVD or patients with CAD. The current qualitative synthesis of literature demonstrates that beyond enhancing nitric oxide bioavailability and lowering blood pressure, regular consumption of tea and its active ingredients such as epigallocatechin gallate may be beneficial in reducing markers of oxidative stress and inflammation. Moreover, the reduction of oxidized low-density lipoprotein and C-reactive protein levels, could be a sign of improved endothelial function in individuals at increased risk of developing CVD. The cumulative evidence also suggests that the development of epigallocatechin gallate as a nutraceutical or enriching foods with this bioactive compound could be a feasible strategy to improve endothelial function and lower CVD-risk. However, well-designed RCTs are still necessary to confirm long-term benefits of tea consumption on vascular health.

Sections du résumé

BACKGROUND AND AIMS
There is a general interest in understanding how the consumption of tea impacts cardiovascular function in individuals at risk of developing cardiovascular disease (CVD). The current review focuses on evidence from randomized controlled trials (RCTs) reporting on associations between tea consumption and endothelial function, in the primary and secondary prevention of coronary artery disease (CAD).
METHODS
PubMed, EMBASE, and Google Scholar databases/search engines were used to identify eligible studies. Included studies had to report on the impact of tea supplementation of endothelial function or CAD related markers. In addition to flow-mediated dilation (FMD), makers of oxidative stress and inflammation such as oxidized low-density lipoprotein and C-reactive protein were considered as determinants of endothelial function. A total of 34 RCTs met the inclusion criteria, and these reported on the impact of tea consumption on endothelial function in individuals at risk of CVD or patients with CAD.
RESULTS
The current qualitative synthesis of literature demonstrates that beyond enhancing nitric oxide bioavailability and lowering blood pressure, regular consumption of tea and its active ingredients such as epigallocatechin gallate may be beneficial in reducing markers of oxidative stress and inflammation. Moreover, the reduction of oxidized low-density lipoprotein and C-reactive protein levels, could be a sign of improved endothelial function in individuals at increased risk of developing CVD.
CONCLUSIONS
The cumulative evidence also suggests that the development of epigallocatechin gallate as a nutraceutical or enriching foods with this bioactive compound could be a feasible strategy to improve endothelial function and lower CVD-risk. However, well-designed RCTs are still necessary to confirm long-term benefits of tea consumption on vascular health.

Identifiants

pubmed: 33487310
pii: S2405-4577(20)31083-4
doi: 10.1016/j.clnesp.2020.11.006
pii:
doi:

Substances chimiques

Tea 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

77-87

Informations de copyright

Copyright © 2020 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest.

Auteurs

Phiwayinkosi V Dludla (PV)

Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg 7505, South Africa; Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona 60131, Italy. Electronic address: pdludla@mrc.ac.za.

Bongani B Nkambule (BB)

School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4000, South Africa.

Sithandiwe E Mazibuko-Mbeje (SE)

Department of Biochemistry, North-West University, Mmabatho 2745, South Africa.

Tawanda M Nyambuya (TM)

School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4000, South Africa; Department of Health Sciences, Namibia University of Science and Technology, Windhoek 9000, Namibia.

Patrick Orlando (P)

Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona 60131, Italy.

Sonia Silvestri (S)

Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona 60131, Italy.

Fabio Marcheggiani (F)

Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona 60131, Italy.

Ilenia Cirilli (I)

Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona 60131, Italy; School of Pharmacy, University of Camerino, Camerino 62032, Italy.

Khanyisani Ziqubu (K)

Department of Biochemistry, North-West University, Mmabatho 2745, South Africa.

Fransina Ndevahoma (F)

Department of Health Sciences, Namibia University of Science and Technology, Windhoek 9000, Namibia.

Vuyolwethu Mxinwa (V)

School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4000, South Africa.

Kabelo Mokgalaboni (K)

School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4000, South Africa.

Jacopo Sabbatinelli (J)

Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona 60126, Italy.

Johan Louw (J)

Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg 7505, South Africa; Department of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa 3886, South Africa.

Luca Tiano (L)

Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona 60131, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH